Clinical Significance of Inflammatory Markers for Evaluating Disease Severity of Mixed-pathogen Bloodstream Infections of Both Spp. and Spp
Overview
Affiliations
Objective: In recent decades, there has been a notable increase in the morbidity and mortality rates linked to bacteremia and candidemia. This study aimed to investigate the clinical significance of inflammatory markers in assessing the disease severity in critically ill patients suffering from mixed-bloodstream infections (BSIs) due to spp. and spp.
Methods: In this retrospective research, patients diagnosed with BSIs who were admitted to the intensive care unit (ICU) during the period of January 2019 to December 2022 were analyzed. The patients were divided into two groups: a mixed-pathogen BSI group with both spp. and spp., and a single-pathogen BSI group with only spp. The study examined the differences in inflammatory marker levels and disease severity, including Acute Physiology and Chronic Health Evaluation (APACHE) II scores, duration of ICU stay, and 30-day mortality, between the two groups. Furthermore, we sought to scrutinize the potential associations among these aforementioned parameters.
Results: The neutrophil-to-lymphocyte ratios (NLRs) and levels of plasma C-reactive protein (CRP), interleukin (IL)-6, IL-8, and tumor necrosis factor-α (TNF-α) in the mixed-pathogen BSI group were higher than those in the single-pathogen BSI group. Spearman's rank correlation analysis showed that NLRs and plasma CRP and IL-6 levels were positively correlated with disease severity in the mixed-pathogen BSI group. Further, the levels of plasma IL-8 and TNF-α were also positively correlated with ICU stay duration and 30-day mortality. In multivariate analysis, plasma CRP and IL-6 levels were independently associated with 30-day mortality.
Conclusion: Mixed-pathogen BSIs caused by spp. and spp. may give rise to increased NLRs and plasma CRP, IL-6, IL-8, and TNF-α levels in comparison to BSI caused by spp. only, thus leading to elevated disease severity in critically ill patients.
Wang D, Wang X, Mu J, Kuang Z, Zhang J, Lu X Ann Med. 2024; 57(1):2438833.
PMID: 39661398 PMC: 11636143. DOI: 10.1080/07853890.2024.2438833.
Zhang G, Wang T, An L, Hang C, Wang X, Shao F Heliyon. 2024; 10(16):e36195.
PMID: 39253154 PMC: 11381600. DOI: 10.1016/j.heliyon.2024.e36195.